Pharmacy
Why a deviation investigation still takes two weeks in the age of AI
- Most of those two weeks is not science. It is finding and assembling the data, which is also where most of the AI sold to pharma quietly stalls.
Issue №041 · 2026-06-24
Daily Briefing · 2026-06-24
Pharmacy
In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy
- In another sign that the FDA is easing its stance toward rare disease drug candidates under new leadership, the agency will reconsider Regenxbio’s gene therapy for an ultra-rare childhood disease, a reversal coming just
Pharmacy
Sanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic disease
- French biopharma Sanofi inked a partnership deal with Pangaea Data to use its AI platform that helps detect Alpha-1 Antitrypsin Deficiency (AATD) that will be distributed to select healthcare systems and low-income commu
Health OS
Prosper AI lands $30M backed by Andreessen Horowitz to build AI workforce for healthcare operations
- Prosper AI banked $30 million to scale its agentic AI platform to power administrative tasks from patient scheduling to insurance verification and patient billing.